Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia

Clinical Infectious Diseases

Volumn 30, Issue 3, 2000, Pages 520-528

  Metlay, Joshua P ^a   Hofmann, Jo ^c,e   Cetron, Martin S ^c   Fine, Michael J ^b   Farley, Monica M ^d   Whitney, Cynthia ^c   Breiman, Robert F ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Snohomish Health District   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFOTAXIME; ERYTHROMYCIN; OFLOXACIN; PENICILLIN DERIVATIVE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; FEMALE; HUMAN; INFECTION RISK; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0034085165     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313716     Document Type: Article

References (37)

1. 1. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271:1831-5.
2. 2. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333:481-6.
3. 3. Doern GV, Brueggemann A. Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
4. 4. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study. Diagn Microbiol Infect Dis 1996; 25: 89-95.
5. 5. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27:764-70.
6. 6. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
7. 7. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146:920-3.
8. 8. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995; 14:885-90.
9. 9. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998; 26:811-38.
10. 10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12.
11. 11. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76.
12. 12. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452-7.
13. 13. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997; 12:423-30.
14. 14. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970-80.
15. 15. Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geo-coding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol 1998; 148:1212-8.
16. 16. Donowitz G, Mandell G. Acute pneumonia. In: Mandell G, Bennett J, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:619-37.
17. 17. Fine MJ, Orloff JJ, Arisumi D, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990; 88:1N-8N.
18. 18. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993; 94:153-9.
19. 19. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
20. 20. Facklam RR, Washington JAI. Streptococcus and related catalase-negative gram-positive cocci. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology. 5th ed. Washington, DC: American Society for Microbiology, 1991:238-67.
21. 21. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Proposed standard M7-A3. 2d ed. Villanova, PA: NCCLS, 1993.
22. 22. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. 3d ed. Villanova, PA: NCCLS, 1994.
23. 23. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
24. 24. Coley CM, Hough LJ, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Causes and timing of death in patients with community-acquired pneumonia. J Gen Intern Med 1996; 11(Suppl):45.
25. 25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
26. 26. Allison P. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995.
27. 27. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med 1995; 10:359-68.
28. 28. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24:1052-9.
29. 29. Nava JM, Bella F, Garau J, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 1994; 19:884-90.
30. 30. Istre GR, Tarpay M, Anderson M, Pryor A, Welch D. Invasive disease due to Streptococcus pneumoniae in an area with a high rate of relative penicillin resistance. J Infect Dis 1987; 156:732-5.
31. 31. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-82.
32. 32. Levin BR, Lipsitch M, Perrot V, et al. The population genetics of antibiotic resistance. Clin Infect Dis 1997; 24(Suppl 1):S9-16.
33. 33. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275: 134-41.
34. 34. Garcia-Leoni ME, Moreno S, Rodeno P, Cercenado E, Vicente T, Bouza E. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. Arch Intern Med 1992; 152:1808-12.
35. 35. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996; 275:194-8.
36. 36. Redd SC, Rutherford GWD, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-7.
37. 37. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29:321-7.